



OPTO CIRCUITS (INDIA) LIMITED.

Date: 20th February 2014

**The Manager,
Department of Corporate Services
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai-400 001.**

**NATIONAL STOCK EXCHANGE OF INDIA LTD,
EXCHANGE PLAZA, BANDRA – KURLA COMPLEX,
BANDRA (E)
MUMBAI – 400 051.**

Dear Sir,

Subject: Press Release.

We would like to inform you that Cardiac Science Corporation, a group company of Opto Circuits (India) Ltd. and a global leader in automated external defibrillators (AEDs), announced today that its Powerheart® G5 AED has received 510(k) market clearance from the U.S. FDA (Food and Drug Administration), allowing the company to begin selling the AED later this year along with its successful Powerheart® G3 product line.

We are enclosing herewith the press release regarding this.

Kindly acknowledge the receipt.

Thanking you,

Truly yours,
for OPTO CIRCUITS (INDIA) LTD.,

Authorised Signatory



Opto Circuits Group Company - Cardiac Science - Receives U.S. FDA 510(k) Clearance to Market New Powerheart G5 AED

New AED Further Strengthens Company's Product Portfolio

Bengaluru, India | Wisconsin, USA | Feb. 20, 2014

Cardiac Science Corporation, a group company of Opto Circuits (India) Ltd. (Bloomberg: OPTC IN; Reuters: OPTO. NS; NSE: OPTOCIRCUI; BSE: 532391) and a global leader in automated external defibrillators (AEDs), announced today that its Powerheart® G5 AED has received 510(k) market clearance from the U.S. FDA (Food and Drug Administration), allowing the company to begin selling the AED later this year along with its successful Powerheart® G3 product line.


"This news is a testament to the commitment shown by our employees who have spent many years of developing, testing and refining the Powerheart G5 so that seasoned and first-time rescuers will have the most reliable, easy-to-use AED in the U.S. marketplace," said Vinod Ramnani, Chairman and Managing Director, Opto Circuits (India) Ltd. "Our product portfolio is now the envy of the AED industry."

The Powerheart family of AEDs is designed to enable rescuers to swiftly provide effective, life-saving therapy to aid a person who has suffered sudden cardiac arrest (SCA), a condition in which the heart suddenly stops beating due to irregularities in its electrical system. The condition strikes as many as 360,000 Americans annually with the majority of cases being fatal, according to the American Heart Association.

However, the American Heart Association notes that at least 20,000 lives could be saved annually by prompt use of AEDs. Ultimately, with broad deployment of AEDs among trained responders, as many as 50,000 deaths due to SCA could be prevented each year—a cause Cardiac Science is firmly behind.

"Cardiac Science has been working to reduce SCA fatalities since we introduced the first fully automated external defibrillator," said Al Ford, Cardiac Science General Manager and Senior Vice President of Sales / Marketing. "The Powerheart G5 and G3 provide a one-two punch in our mission to provide every company, school and public place with a potentially life-saving AED."

The Powerheart G5 will be available for purchase in the United States later this year.



About Cardiac Science

Cardiac Science, a group company of Opto Circuits (India) Ltd., develops, manufactures, and markets automated external defibrillators (AED). The company also provides a portfolio of training, maintenance, and support services for AEDs. Cardiac Science is headquartered in Waukesha, Wisconsin. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 1.800.426.0337 or visit <http://www.cardiacscience.com>.

About Opto Circuits (India) Limited

Opto Circuits (India) Ltd. (OCI) is a vertically integrated multinational medical technology Group that specializes in primary, acute and critical care products for the global markets. Group companies such as Cardiac Science, Criticare, Eurocor, Mediaid, AMDL and Unetixs Vascular are leaders in vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies. Our USFDA listed and CE marked products are marketed in more than 150 countries and sold through direct and indirect sales channels across many emerging and developed economies. We've been ranked in Forbes' Asia's 200 Best under a Billion lists in 2008, 2009 and 2011. For more information, please visit www.optoindia.com.

Opto Circuits (India) Ltd.

Media - media@optoindia.com

Investors - ir@optoindia.com

+91 80- 28521040-42

